Targeting Pathologic Cells to Preserve Biological Youth (Dr. Marco Quarta, Rubedo Life Sciences)
Listen now
Dr. Marco Quarta, CEO and Co-founder of Rubedo Life Sciences, joins Chris on today’s episode to discuss his company’s strategy of targeting pathologic cells to develop therapeutics for chronic degenerative conditions. The conversation covers the evolving definition of senescence and the challenges of identifying and classifying pathologic cells, which vary across different tissues and indications. Marco also announces the upcoming Senotherapeutic Summit in November, which will bring together stakeholders from different fields to advance therapeutic research.  Marco and Chris also review Rubedo Life Sciences' clinical development approach: targeting the aging process with the goal of helping healthy stem and immune cells to repair. They then go on to discuss the funding and work required for the selection and nomination of a lead candidate for a project, the importance of having access to primary clinical samples to test efficacy, and the subsequent steps of the grant awarding process. The conversation then turns to the value of having multiple programs running simultaneously.  Tune in today to learn more about  the ‘sneaky’ process of senescence that accelerates aging, the toxicity of these rare cells and the development of small molecules that can target them, the complexities of developing new therapies, and the value of having a robust pipeline of programs to advance therapeutic R&D. The Finer Details: Defining pathological cells and their role in chronic degenerative conditionsIdentifying, classifying, and targeting senescent cellsThe need for a focused effort in identifying specific targets for therapeuticsThe evolution of the definition of senescence and the existence of multiple types of senescent cellsThe Senotherapeutic Summit in November and its goal of advancing the field of therapeuticsRunning multiple programs simultaneouslyThe upcoming event in Saudi Arabia aimed at accelerating and promoting healthy longevity. Quotes: "These are aberrant cells, dysfunctional cells, and maladaptive cells that are contributing to shift the microenvironment and leading to progression of chronic degenerative conditions, driving chronic inflammation, fibrosis, stem cell depletion, and cancer." "There are no universal pathologic cells across all tissues or indications. So it really depends on your question and finding targets associated with those that you can really go after in a drug discovery pipeline to generate therapeutics."  "We are hoping to push forward the conversation about what senescent cells are, how we can classify them, and how we can move forward with targeting these cells." "We are testing back to back multiple indications including for example, chronic age related atopic dermatitis and others." "And it's a very important event that we'll have major stakeholders from high level government officials and scientists and innovators business leaders and really the idea of promoting a healthy longevity and how can we accelerate this." Links:  Email questions, comments, and feedback to [email protected] Translating Aging on Twitter: @bioagepodcast BIOAGE Labs Website BIOAGE Labs Twitter @bioagelabs BIOAGE Labs LinkedIn Rubedo...
More Episodes
This special episode features a panel discussion moderated by Chris Patil at the 2023 SynBioBeta conference. The panel brings together leaders from the synthetic biology and longevity communities to explore opportunities for collaboration and cross-pollination between these fields. Panelists...
Published 05/31/23
In this episode of Translating Aging, host Chris Patil is joined by Dr. Courtney Hudson-Paz, the Founder and Program Director of the Time Initiative, an organization whose mission is to build a network of undergraduate leaders in aging biology.
Published 05/17/23
Published 05/17/23